Epidemiology and Survival Outcomes of Synchronous and Metachronous Brain Metastases

Neurosurgeons Chetan Bettegowda and Jordina Rincon-Torroella discuss results from their retrospective study about the incidence and survival outcomes of brain metastases over the past decade. Using data from the TriNetX Diamond Network and diagnoses and therapies identified with ICD-10 and CPT codes, they found (1) a substantial rate of brain metastases present within 2-6 months of primary cancer, which may guide future recommendations on intracranial staging, and (2) antineoplastic and radiation therapy prior to the development of brain metastases may prolong time before metastasis and improve survival.